5 Key Takeaways
-
1
The Phase 1b LOTUS trial investigates EB-105, a novel pentavalent trispecific antibody targeting multiple inflammatory pathways for diabetic macular edema.
-
2
EB-105 aims to improve treatment efficacy by addressing IL-6R alongside VEGF-A, VEGF-B, PIGF, and ANG-2 to reduce retinal edema.
-
3
The trial included 13 patients with DME, showing EB-105 was safe, well tolerated, and resulted in significant improvements in BCVA and CST.
-
4
Patients experienced a mean 7-letter gain in BCVA and approximately 100 μm reduction in CST after a single EB-105 injection.
-
5
Future studies are planned for Q3 2025 to further evaluate EB-105's efficacy and safety in a Phase 1-2 multiple ascending-dose trial.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.